HC Wainwright has initiated coverage on ImmunityBio, Inc (NASDAQ:IBRX). The company’s lead asset is Anktiva (nogapendekin alfa inbakicept-pmln) solution for intravesical use, approved by the Food and Drug Administration indicated with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive bladder carcinoma in situ (CIS) with or without papillary tumors.
Also Read: ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
HC Wainwright analyst Andres Y. Maldonado writes that Anktiva will follow a different market path than the two latest FDA-approved treatments for high-risk bladder cancer—Merck & Co Inc’s (NYSE:MRK) Keytruda and Ferring Pharmaceutical’s Adstiladrin—both of which have faced hurdles after launch.
Keytruda’s adoption has been slow because …
